Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hMaxi-K
- Development stage
- Phase 2
- Lead developer
- Ion Channel Innovations
- Modality
- Gene Silencing → Gene Therapies, Gene Editing → Gene Therapies, Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Gene Addition/Replacement → Gene Therapies
- Administration
- Intracavernosal, Intradetrusor
01
Overview
hMaxi-K is a gene therapy consisting of a naked DNA plasmid encoding the human cDNA for the alpha (pore-forming) subunit of the human smooth muscle Maxi-K channel (also known as BK or hSlo channel). The therapy is designed to increase expression of this potassium channel in smooth muscle cells, leading to increased potassium efflux, decreased calcium influx, and subsequent relaxation of smooth muscle. This mechanism underlies its intended use for conditions such as erectile dysfunction (ED) and overactive bladder (OAB), where enhanced smooth muscle relaxation can improve symptoms. The product was developed by Ion Channel Innovations and later advanced by Sumitomo Pharma America (formerly Urovant Sciences). Clinical studies have shown promising safety results and preliminary efficacy in both ED and OAB; however, development has been discontinued for these indications[1][2][3][4][5][6].
- Other names
- hMaxi-KURO 902URO902URO-902pVAX/hSlo
02
Targets
KCNMA1 (Calcium-activated potassium channel subfamily M alpha member 1)
Beyond the preview
Go deeper on hMaxi-K.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hMaxi-K.